Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes the company from its competitors.
You were one of the first employees of Celgene in Europe assisting with the establishment of the commercial organization back in 2006 and laying the groundwork for launching blockbuster REVLIMID®. What was the initial rationale behind basing the company’s European headquarters in Switzerland?
Switzerland was actually a natural choice to start-up operations because the local ecosystem is well geared up to supporting a highly specialized activity
